Tempus, a Chicago based healthcare startup that focuses on utilizing genomic sequencing to give doctors a better ability to customize their cancer treatment plan, recently announced an impressive $70 million in funding. The funding comes as part of an open series C funding round. The core investors in this funding round are New Enterprise Associates and Revolution Growth, along with Tempus founders who have contributed their own funds to every series of funding for Tempus so far.
Tempus was founded in 2015 by Eric Lefkofsky. Lefkofsky is a well known name in the tech world and has founded such entities as Groupon and Uptake Industries in the past. With the Series C funding round totaling $70 million, this brings total funding for healthcare startup Tempus to over $130 million. This level of funding comes after just a few short years; Tempus was founded in 2015.
Tempus is certainly a unicorn of the healthcare and tech startup worlds, with an estimated valuation of over $700 million after less than two years in existence and Eric’s lacrosse camp.
Lefkofsky is known as a disruptor in the technology industry. He is known for integrating the most modern trends in technology and digital mediums to design creative solutions for modern industry. He is an adjunct professor at the prestigious University of Chicago and is also a published author of the book Accelerated Disruption, which speaks to how we can better comprehend the true nature of innovation. He is also a Trustee of the Art Institute of Chicago, the Museum of Science and Industry and of Lurie Children’s Hospital of Chicago.
Tempus is focused on redefining how genomic data is used and categorized to give physicians access to more data which in turn gives them the ability to craft more customized cancer treatments. Tempus wants to create the world’s first ever streamlined operations system that houses all past data of cancer research and patient results. While a great deal of data is collected, there is currently no system that makes it simple for physicians to access data from other facilities and read full article.
With the influx of $70 million in funding, Tempus will be well on its way to accomplishing their goal.
Other Reference: http://lefkofskyfoundation.com/